BeiGene (BGNE) Revenue & Revenue Breakdown

Overview ForecastOwnership Financials Chart

BeiGene Revenue Highlights

Latest Revenue (Y)

$2.46B

Latest Revenue (Q)

$929.17M

Main Segment (Y)

Collaboration

Main Geography (Y)

UNITED STATES

BeiGene Revenue by Period

BeiGene Revenue by Year

Date	Revenue	Change
2023-12-31	$2.46B	73.65%
2022-12-31	$1.42B	20.37%
2021-12-31	$1.18B	280.83%
2020-12-31	$308.87M	-27.87%
2019-12-31	$428.21M	116.03%
2018-12-31	$198.22M	-16.85%
2017-12-31	$238.39M	22179.16%
2016-12-31	$1.07M	-87.86%
2015-12-31	$8.82M	-32.37%
2014-12-31	$13.04M	16.93%
2013-12-31	$11.15M	-

BeiGene generated $2.46B in revenue during NA 2023, up 73.65% compared to the previous quarter, and up 1240.43% compared to the same period a year ago.

BeiGene Revenue by Quarter

Date	Revenue	Change
2024-06-30	$929.17M	23.62%
2024-03-31	$751.65M	18.48%
2023-12-31	$634.41M	-18.80%
2023-09-30	$781.31M	31.25%
2023-06-30	$595.26M	32.93%
2023-03-31	$447.80M	17.81%
2022-12-31	$380.10M	-1.94%
2022-09-30	$387.63M	13.48%
2022-06-30	$341.57M	11.40%
2022-03-31	$306.63M	43.30%
2021-12-31	$213.98M	3.65%
2021-09-30	$206.44M	37.63%
2021-06-30	$149.99M	-75.24%
2021-03-31	$605.87M	505.27%
2020-12-31	$100.10M	9.90%
2020-09-30	$91.08M	38.77%
2020-06-30	$65.64M	26.08%
2020-03-31	$52.06M	-8.50%
2019-12-31	$56.89M	13.46%
2019-09-30	$50.14M	-79.40%
2019-06-30	$243.35M	212.65%
2019-03-31	$77.83M	32.66%
2018-12-31	$58.67M	8.24%
2018-09-30	$54.20M	2.65%
2018-06-30	$52.80M	62.25%
2018-03-31	$32.54M	79.07%
2017-12-31	$18.17M	-91.75%
2017-09-30	$220.21M	100.00%
2017-06-30	-	100.00%
2017-03-31	-	-100.00%
2016-12-31	$137.13M	100.00%
2016-09-30	-	-100.00%
2016-06-30	$393.00K	-41.95%
2016-03-31	$677.00K	-85.52%
2015-12-31	$4.68M	238.91%
2015-09-30	$1.38M	-
2015-06-30	$1.38M	0.07%
2015-03-31	$1.38M	-0.14%
2014-12-31	$1.38M	-78.74%
2014-09-30	$6.50M	-

BeiGene generated $929.17M in revenue during Q2 2024, up 23.62% compared to the previous quarter, and up 207.50% compared to the same period a year ago.

BeiGene Revenue Breakdown

BeiGene Revenue Breakdown by Product

Annual Revenue by Product

Product/Service	Dec 23	Dec 22	Dec 21	Dec 20	Dec 19
License	$71.98M	$71.98M	$484.65M	-	-
Collaboration	$268.93M	$161.31M	-	$205.62M	-
Right To Access Intellectual Property Revenue	$104.48M	$3.98M	-	-	-
Collaboration Research And Development Service	$79.43M	$53.67M	-	$27.98M	-
Collaboration Other	$213.45M	$213.45M	-	-	$150.00M
Collaboration Reimbursement Of Research And Development Costs	-	-	-	-	$27.63M
License Revenue	-	-	-	-	-

BeiGene's latest annual revenue breakdown by segment (product or service), as of Dec 23: Collaboration (36.43%), Collaboration Other (28.91%), Right To Access Intellectual Property Revenue (14.15%), Collaboration Research And Development Service (10.76%), and License (9.75%).

Quarterly Revenue by Product

Product/Service	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19
Right To Access Intellectual Property Revenue	-	$52.50M	$51.98M	$26.25M	$26.25M	$26.25M	$26.25M	$26.25M	-	-	-	-	-	-	-	-	-	-	-	-
Collaboration Other	$4.73M	-	$213.45M	$213.45M	$213.45M	$213.45M	$213.45M	$213.45M	-	-	-	-	$150.00M	-	-	-	-	-	-	-
Collaboration Research And Development Service	-	$20.38M	$59.05M	$13.56M	$6.82M	$9.83M	$10.81M	$13.43M	$13.98M	$11.37M	$15.11M	-	-	-	-	-	$25.74M	-	-	-
Collaboration	$4.73M	$189.90M	$41.52M	$41.07M	$38.12M	$37.06M	$45.05M	-	-	-	-	-	$185.20M	-	-	-	-	-	-	-
License	-	-	$71.98M	$71.98M	$71.98M	$71.98M	$71.98M	$71.98M	-	-	$484.65M	-	-	-	-	-	-	-	-	-
Product	-	-	-	-	-	$339.02M	$54.22M	$100.10M	-	-	-	-	-	-	-	-	-	-	-	-
Collaboration Reimbursement Of Research And Development Costs	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$9.46M

BeiGene's latest quarterly revenue breakdown by segment (product or service), as of Mar 24: Collaboration Other (50.00%), and Collaboration (50.00%).

BeiGene Revenue Breakdown by Country

Annual Revenue by Country

Country	Dec 23	Dec 22	Dec 21	Dec 20	Dec 19
All Other Countries Except China And United States Of America	$28.98M	$73.26M	$163.84M	-	$71.97M
CHINA	$1.10B	$840.03M	$517.17M	$290.65M	$221.56M
Europe	$202.01M	-	-	-	-
UNITED STATES	$1.13B	$18.23M	$134.69M	-	-

BeiGene's latest annual revenue breakdown by geography, as of Dec 23: UNITED STATES (45.84%), CHINA (44.77%), Europe (8.21%), and All Other Countries Except China And United States Of America (1.18%).

Quarterly Revenue by Country

Country	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Sep 22	Jun 22	Mar 22	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Sep 18
All Other Countries Except China And United States Of America	$12.96M	-	$9.56M	$47.13M	$35.87M	$19.57M	$14.82M	$16.47M	$4.19M	$3.51M	$149.93M	-	-	-	-	-	$64.82M	$7.14M	$5.51M	-
CHINA	$320.38M	$271.33M	$287.94M	$295.78M	$246.91M	$233.27M	$212.43M	$190.74M	$158.78M	$122.64M	$95.98M	$91.34M	$85.38M	$62.58M	$51.34M	$55.85M	$50.14M	$58.14M	$57.42M	$38.45M
Europe	$66.86M	$116.43M	$85.58M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
UNITED STATES	$351.46M	$477.64M	$398.23M	$252.35M	$8.76M	$5.70M	$3.06M	$717.00K	$1.04M	-	$120.38M	$13.27M	$10.24M	-	-	-	-	-	-	-

BeiGene's latest quarterly revenue breakdown by geography, as of Mar 24: UNITED STATES (46.76%), CHINA (42.62%), Europe (8.90%), and All Other Countries Except China And United States Of America (1.72%).

BeiGene Peer Comparison by Revenue

Ticker	Company	Last Year Revenue	Last Quarter Revenue
INCY	Incyte	$3.70B	$962.99M
BGNE	BeiGene	$2.46B	$929.17M
BMRN	BioMarin Pharmaceutical	$2.42B	$733.87B
IONS	Ionis Pharmaceuticals	$787.65M	$225.25M
APLS	Apellis Pharmaceuticals	$366.28M	$176.57M
LEGN	Legend Biotech	$285.14M	$93.99M
ASND	Ascendis Pharma	$266.72M	$95.89M
BPMC	Blueprint Medicines	$249.38M	$128.18M
TVTX	Travere Therapeutics	$145.24M	$62.90M
KRYS	Krystal Biotech	$50.70M	$83.84M
IMAB	I-Mab	$27.64M	$1.10M
ARWR	Arrowhead Pharmaceuticals	$3.55M	-
AKRO	Akero Therapeutics	-	-
PCVX	Vaxcyte	-	-
IMVT	Immunovant	-	-

BGNE Revenue FAQ

What is BeiGene’s yearly revenue?

BeiGene's yearly revenue for 2023 was $2.46B, representing an increase of 73.65% compared to 2022. The company's yearly revenue for 2022 was $1.42B, representing an increase of 20.37% compared to 2021. BGNE's yearly revenue for 2021 was $1.18B, representing an increase of 280.83% compared to 2020.

What is BeiGene’s quarterly revenue?

BeiGene's quarterly revenue for Q2 2024 was $929.17M, a 23.62% increase from the previous quarter (Q1 2024), and a 56.09% increase year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $751.65M, a 18.48% increase from the previous quarter (Q4 2023), and a 67.85% increase year-over-year (Q1 2023). BGNE's quarterly revenue for Q4 2023 was $634.41M, a -18.80% decrease from the previous quarter (Q3 2023), and a 66.91% increase year-over-year (Q4 2022).

What is BeiGene’s revenue growth rate?

BeiGene's revenue growth rate for the last 3 years (2021-2023) was 109.03%, and for the last 5 years (2019-2023) was 474.20%.

What are BeiGene’s revenue streams?

BeiGene's revenue streams in c 23 are License, Collaboration, Right To Access Intellectual Property Revenue, Collaboration Research And Development Service, and Collaboration Other. License generated $71.98M in revenue, accounting 9.75% of the company's total revenue Collaboration generated $268.93M in revenue, accounting 36.43% of the company's total revenue, up 66.72% year-over-year. Right To Access Intellectual Property Revenue generated $104.48M in revenue, accounting 14.15% of the company's total revenue, up 2525.71% year-over-year. Collaboration Research And Development Service generated $79.43M in revenue, accounting 10.76% of the company's total revenue, up 48.00% year-over-year. Collaboration Other generated $213.45M in revenue, accounting 28.91% of the company's total revenue

What is BeiGene’s main source of revenue?

For the fiscal year ending Dec 23, the largest source of revenue of BeiGene was Collaboration. This segment made a revenue of $268.93M, representing 36.43% of the company's total revenue.